Skye Bioscience, Inc. Common Stock (SKYE NASDAQ) stock market data APIs
$1.2911
0.08(6.2%)
as of October 30, 2026
Try our APIs with
free plan!
Skye Bioscience, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Prev. Close
1.2911
Open
1.373
High
1.427
Low
1.2787
52 wk Range
0.2552-2.25
Market Cap
5 667 K
Shares Outstanding
4 428 K
EPS
-0.27
Beta
2.859
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Skye Bioscience, Inc. Common Stock data using free add-ons & libraries
Get Skye Bioscience, Inc. Common Stock Fundamental Data
Skye Bioscience, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -47 366 696
- Earnings Per Share: -10
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Skye Bioscience, Inc. Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-14
- EPS/Forecast: -0.29
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Skye Bioscience, Inc. Common Stock News
New
The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea
The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures. A single clinical result can send a stock soaring, wipe out years of gains, or ...
Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy
Earnings Call Insights: Skye Bioscience (SKYE) Q4 2025 MANAGEMENT VIEW * CEO Punit Dhillon outlined recent progress for nimacimab, highlighting the transition from promising early signals to a rob...
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg IV cohorts;Received written FDA Type C meeting minutes; ...
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions of Elektrofi's Hypercon™ Tech...
Get Skye Bioscience, Inc. Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.